(Q33414335)

26 July 2017

Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer (English)

1 reference

26 July 2017

metastatic breast cancer

1 reference

Jessica M Baron

1

1 reference

PubMed ID

24682654

26 July 2017

Bonnie L Boster

series ordinal

2

1 reference

PubMed ID

24682654

26 July 2017

Chad M Barnett

series ordinal

3

1 reference

26 July 2017

27 March 2014

1 reference

Journal of Oncology Pharmacy Practice

26 July 2017

1 reference

26 July 2017

21

1 reference

26 July 2017

2

1 reference

26 July 2017

132-142

1 reference

Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer

26 July 2017

1 reference

https://api.crossref.org/works/10.1177%2F1078155214527144

Trastuzumab: triumphs and tribulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155214527144

Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155214527144

Semi-mechanistic population pharmacokinetic model of multivalent trastuzumab emtansine in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155214527144

Semisynthetic maytansine analogues for the targeted treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155214527144

Linked-in: design and efficacy of antibody drug conjugates in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155214527144

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155214527144

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155214527144

Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155214527144

A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155214527144

A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155214527144

New methods allowing the detection of protein aggregates: a case study on trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155214527144

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155214527144

A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155214527144

Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155214527144

Trastuzumab emtansine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155214527144

High-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1)--mediated inhibition of platelet production

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155214527144

21 January 2018

Identifiers

DOI

10.1177/1078155214527144

1 reference

26 July 2017

1 reference

PubMed ID

24682654